Krestin acts as a selective TLR2 agonist, and activates both innate and adaptive immune systems; the anti-tumor activity of krestin is dependent on cytotoxic T cells and natural killer cells, but not dependent on CD4+ T cells. Here, TLR2 is linked to neoplasm.